This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pfizer Rises 5.6% in a Month: How Should You Play the Stock?
by Kinjel Shah
Investors may stay invested in PFE stock to see how its new growth drivers perform
VKTX Stock Loses More Than 20% in Six Months: Should You Buy the Dip?
by Sundeep Ganoria
Despite the rising competition in the obesity space, we believe that there is room for smaller biotechs like Viking Therapeutics to grab a share of this booming market.
Why Novo Nordisk (NVO) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here is What to Know Beyond Why Novo Nordisk A/S (NVO) is a Trending Stock
by Zacks Equity Research
Novo Nordisk (NVO) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Why Novo Nordisk (NVO) Dipped More Than Broader Market Today
by Zacks Equity Research
In the most recent trading session, Novo Nordisk (NVO) closed at $85.73, indicating a -1.88% shift from the previous trading day.
J&J Trading Near 52-Week Low: Should You Sell the Stock?
by Kinjel Shah
Those who own the stock may stay invested for some time as J&J looks optimistic about a better performance in 2025.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Pharma Stock Roundup: NVO's Obesity Study Failure, FDA Nod to PFE, LLY
by Kinjel Shah
NVO's novel obesity candidate shows lower-than-expected weight loss in the study. FDA approves LLY's Zepbound for sleep apnea.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Novo Nordisk (NVO) Stock Drops Despite Market Gains: Important Facts to Note
by Zacks Equity Research
In the latest trading session, Novo Nordisk (NVO) closed at $87.37, marking a -1.51% move from the previous day.
Novo Nordisk Stock Plunges 18% in a Week: What Should Investors Do?
by Ahan Chakraborty
NVO stock declines after a recent obesity study setback and intense competition from market rivals but offers long-term growth potential.
NVO Stock Plunges as Obesity Drug CagriSema Misses Target in Phase III
by Zacks Equity Research
Novo Nordisk stock slumps as the 22.7% weight loss achieved with its next-gen obesity candidate, CagriSema, in a phase III study misses its guidance of 25%.
Lilly's Zepbound Receives FDA Approval for Sleep Apnea
by Zacks Equity Research
FDA approves LLY's obesity drug Zepbound for its second indication, moderate-to-severe obstructive sleep apnea.
LLY Stock Up as FDA Removes Mounjaro, Zepbound From Shortage List
by Zacks Equity Research
Eli Lilly stock gains as the FDA removes tirzepatide drugs from the drug shortage list following a thorough reevaluation.
Earnings Growth & Price Strength Make Novo Nordisk (NVO) a Stock to Watch
by Zacks Equity Research
The Zacks Focus List offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.
Merck Enters Obesity Space, Buys Rights to Hansoh's Oral GLP-1 Drug
by Zacks Equity Research
Merck gets exclusive global rights to develop, manufacture and commercialize GLP-1 receptor agonist, HS-10535, from Hansoh Pharma.
Here's Why VKTX Stock Plummeted 18% on Wednesday
by Zacks Equity Research
The selloff in Viking Therapeutics stock comes after some investors raised concerns for the small biotech amid Merck's entry into the obesity space.
NVO to Invest $1.2B in New Rare Disease Drugs Facility in Denmark
by Zacks Equity Research
Novo Nordisk is set to invest $1.2 billion for a new facility in Odense, Denmark, to produce various product types for rare diseases, including haemophilia.
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
ABBV's Acquisition Spree Continues: Buy, Sell or Hold the Stock?
by Kinjel Shah
Investors who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth next year.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Novo Nordisk (NVO) Stock Moves -1.53%: What You Should Know
by Zacks Equity Research
Novo Nordisk (NVO) closed at $106.95 in the latest trading session, marking a -1.53% move from the prior day.
NVO Gets Positive CHMP Opinion in EU for Ozempic Expanded Use in CKD
by Zacks Equity Research
Novo Nordisk's diabetes drug, Ozempic, receives positive CHMP opinion in the EU for expanded use in T2D and CKD patients.
Eli Lilly Reports Positive Data From Late-Stage Breast Cancer Study
by Zacks Equity Research
Data from a late-stage study shows that LLY's experimental oral drug benefited certain breast cancer patients when used as both a combination and monotherapy.
PFE or NVO: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PFE vs. NVO: Which Stock Is the Better Value Option?